Georgiamune - Crunchbase Company Profile & Funding

Q: Who invested in Georgiamune?

Georgiamune has 9 investors including Bioventures Investors And Mubadala Capital Ventures.

Q: When was the last funding round for Georgiamune?

Georgiamune closed its last funding round on obfuscated from a Series A round.

Q: How much funding has Georgiamune raised to date?

Georgiamune has raised obfuscated.

Overview

Georgiamune

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About Georgiamune

CB Rank

29474

Georgiamune is a biotechnology company developing next-generation immunotherapeutics for cancer and autoimmune diseases.

Founded

obfuscation

Private

Series A

Gaithersburg, Maryland, United States

11-50

www.georgiamune.com

Biotechnology

Health Care

Therapeutics

Funding Rounds

Series A

OBF

obfuscation

Venture - Series Unknown

OBF

obfuscation

Key People

Samir N. Khleif: Founder and CEO

Details

Legal Name

Georgiamune, Inc.

Operating Status

Active

Company Type

For Profit

Founders

Samir N. Khleif

About the Company

Georgiamune is an immunotherapy company focused on oncology breakthroughs. The company employs next-generation immunotherapeutic and homeostatic therapies for cancer and autoimmune illnesses, allowing patients to recover quickly from cancer.

Contact Email

info@georgiamune.com

Predictions & Insights

Growth Prediction

See this Growth Prediction

Top Contributing Factors

Product Launches

Products & Services

GIM-122

A dual-functioning antibody designed to overcome cancer-mediated immune suppression and stimulate activated T cells to enhance antitumor activity.

GIM-531

An oral small molecule that selectively inhibits regulatory T cells (Tregs) to reprogram the tumor microenvironment and enable immune-mediated tumor elimination.

Research & Development

Georgiamune is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated

...

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Series A - Georgiamune	8	obfuscated obfuscation	General Catalyst, Parker Institute for Cancer Immunotherapy	Series A
obfuscated obfuscation	Series A - Georgiamune	8	obfuscated obfuscation	General Catalyst, Parker Institute for Cancer Immunotherapy	Series A
obfuscated obfuscation	Series A - Georgiamune	8	obfuscated obfuscation	General Catalyst, Parker Institute for Cancer Immunotherapy	Series A
obfuscated obfuscation	Series A - Georgiamune	8	obfuscated obfuscation	General Catalyst, Parker Institute for Cancer Immunotherapy	Series A
obfuscated obfuscation	Series A - Georgiamune	8	obfuscated obfuscation	General Catalyst, Parker Institute for Cancer Immunotherapy	Series A

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Series A - Georgiamune	8	obfuscated obfuscation	General Catalyst, Parker Institute for Cancer Immunotherapy	Series A
obfuscated obfuscation	Series A - Georgiamune	8	obfuscated obfuscation	General Catalyst, Parker Institute for Cancer Immunotherapy	Series A
obfuscated obfuscation	Series A - Georgiamune	8	obfuscated obfuscation	General Catalyst, Parker Institute for Cancer Immunotherapy	Series A
obfuscated obfuscation	Series A - Georgiamune	8	obfuscated obfuscation	General Catalyst, Parker Institute for Cancer Immunotherapy	Series A
obfuscated obfuscation	Series A - Georgiamune	8	obfuscated obfuscation	General Catalyst, Parker Institute for Cancer Immunotherapy	Series A

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
Bioventures Investors	—	Series A - Georgiamune	—
Bioventures Investors	—	Series A - Georgiamune	—
Bioventures Investors	—	Series A - Georgiamune	—
Bioventures Investors	—	Series A - Georgiamune	—
Bioventures Investors	—	Series A - Georgiamune	—